Topic cluster
GLP-1 Safety, Side Effects & Stopping Safely
Patients starting a GLP-1 are typically more anxious about adverse effects than about efficacy — and the published evidence on safety is often very different from what circulates in social media. This cluster collects the trial-anchored safety articles on the site: side effect frequencies from the actual STEP and SURMOUNT adverse-event tables, the thyroid cancer black-box history, the liver and kidney evidence base, and the practical questions about surgery prep and how to discontinue safely.
10 research articles in this cluster · last updated 2026-04-08
GLP-1 Side Effects: A Plain-English Guide to What the Trials Actually Showed
What the STEP-1 and SURMOUNT-1 Phase 3 trials actually measured for nausea, vomiting, pancreatitis, gallbladder events, thyroid risk, and the so-called 'Ozempic face' — with every percentage cited to its source PMID. Includes the counterintuitive finding that semaglutide nausea rates exceeded tirzepatide's in head-to-head comparison.
GLP-1 Side Effect Q&A: Headache, Sulfur Burps, Brain Fog, Mood, Acne, and 12 Other Patient Questions
Specific patient-reported GLP-1 side effects with verified rates from STEP-1, SURMOUNT-1, and the FDA prescribing information adverse reactions tables. Includes the headache rate (14.2% sema vs 10% placebo), the sulfur-burp mechanism, the FDA suicidal ideation review conclusion, and the emerging brain fog FDA pharmacovigilance signal.
Does GLP-1 Cause Cancer? MTC, Pancreatic Evidence (2026)
Two thousand patients a month search 'does semaglutide cause cancer.' This is the evidence-based answer: the FDA boxed warning for medullary thyroid carcinoma comes from rodent studies, has not been replicated in humans, but is taken seriously enough to contraindicate GLP-1s in MEN2 and personal/family MTC history. The pancreatic cancer signal has been investigated in multiple large cohorts and found to be null. The 2023 BMJ thyroid signal paper and the 2024 EMA review.
Does GLP-1 Cause Liver Damage? NAFLD & MASH Evidence
Patients worry GLP-1s damage the liver. The trial evidence — Newsome 2021, SYNERGY-NASH 2024, STEP-1 and SURMOUNT-1 sub-analyses — shows the opposite: semaglutide and tirzepatide reduce liver fat and improve MASLD/MASH.
Can You Drink Alcohol on a GLP-1? Safety & Cravings Evidence
Two thousand patients a month search 'can you drink on semaglutide.' This is the evidence-based answer: there is no FDA contraindication, but GLP-1s lower alcohol tolerance, increase hypoglycemia risk in diabetics, and — unexpectedly — appear to reduce alcohol cravings in observational and trial data. Includes the practical drinking guidance and the red flags that mean stop.
What Happens When You Stop Semaglutide? STEP-4 Evidence
Semaglutide doesn't work like an antibiotic — you don't take a course and stay better. The STEP-4 withdrawal trial and the STEP-1 one-year extension showed that participants regain ~64% of lost weight within months of discontinuation. We walk through the actual trial data, mechanism, and what it means for anyone considering stopping.
How to Taper Off Semaglutide and Tirzepatide Safely: The Discontinuation Protocol Guide
Stopping a GLP-1 medication isn't the same as skipping a few weeks. The STEP-4 trial showed that patients who stopped semaglutide regained 67% of their lost weight within a year. This guide walks through the evidence-based tapering options, when to stop versus continue, and the rebound prevention protocol.
GLP-1 Side Effects Duration: Fatigue, Hair Loss, and How Long Everything Actually Lasts
A trial-data-grounded guide to the three most-searched GLP-1 side effects that patients worry about most: fatigue ('does semaglutide make you tired?'), hair loss ('does tirzepatide cause hair loss?'), and how long standard GI side effects actually last. Covers onset timing, expected duration, resolution patterns, and what the STEP and SURMOUNT trials actually reported.
GLP-1 Nausea: The Practical Management Guide (Trial Rates, Timeline, and What Actually Helps)
Nausea is the #1 reason people quit GLP-1s. STEP-1 reported 44% on semaglutide, SURMOUNT-1 reported 33% on tirzepatide, and most of it lands in the first 8 weeks. This guide breaks down the exact rates, the typical timeline, and the practical strategies that have actual evidence behind them — plus the red flags that mean you should call your prescriber.
Stopping GLP-1s Before Surgery: ASA Aspiration Guidance
The American Society of Anesthesiologists issued specific GLP-1 hold guidance in 2023 and updated it in 2024 because of aspiration cases under anesthesia. This is the patient-facing version: when to hold, when not to, what to tell your surgeon and anesthesia team, and what the actual evidence behind the guidance is.